HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
DOTALAN
binds tumors, perhaps by binding hsst(2-5); structure in first source
Also Known As:
111In-DOTALAN; 90Y-DOTALAN; DOTA-beta-naphthyl(1)-lanreotide; DOTA-betaNal(1)-lanreotide
Networked:
1
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
DOTALAN: 1
Polycyclic Compounds: 6
Macrocyclic Compounds: 15
Cyclic Peptides: 530
DOTALAN: 1
Amino Acids, Peptides, and Proteins: 1
Peptides: 82426
Cyclic Peptides: 530
DOTALAN: 1
Related Diseases
1.
Prostatic Neoplasms (Prostate Cancer)
11/01/1999 - "
111In-/90Y-DOTALAN exhibited a similar high binding affinity (Kd, 1-15 nM) for the human breast cancer cell lines T47D and ZR75-1, the prostate cancer cell lines PC3 and DU145, the colonic adenocarcinoma cell line HT29, the pancreatic adenocarcinoma cell line PANC1, and the melanoma cell line 518A2.
"
2.
Neoplasms (Cancer)
11/01/1999 - "
Taken together, our results indicate that 111In-/90Y-DOTALAN binds to a broad range of primary human tumors and tumor cell lines, probably via binding to hsst2-5.
"
11/01/1999 - "
We have developed a 111In-/90Y-labeled SST analog, DOTA-(D)betaNal1-lanreotide (DOTALAN), for tumor diagnosis and therapy.
"
11/01/1999 - "
111In-/90Y-DOTALAN bound with high affinity (dissociation constant, Kd, 1-12 nM) to a number of primary human tumors (n = 31) such as intestinal adenocarcinoma (n = 17; 150-4000 fmol/mg protein) or breast cancer (n = 4; 250-9000 fmol/mg protein).
"
3.
Melanoma (Melanoma, Malignant)
11/01/1999 - "
111In-/90Y-DOTALAN exhibited a similar high binding affinity (Kd, 1-15 nM) for the human breast cancer cell lines T47D and ZR75-1, the prostate cancer cell lines PC3 and DU145, the colonic adenocarcinoma cell line HT29, the pancreatic adenocarcinoma cell line PANC1, and the melanoma cell line 518A2.
"
4.
Breast Neoplasms (Breast Cancer)
11/01/1999 - "
111In-/90Y-DOTALAN exhibited a similar high binding affinity (Kd, 1-15 nM) for the human breast cancer cell lines T47D and ZR75-1, the prostate cancer cell lines PC3 and DU145, the colonic adenocarcinoma cell line HT29, the pancreatic adenocarcinoma cell line PANC1, and the melanoma cell line 518A2.
"
11/01/1999 - "
111In-/90Y-DOTALAN bound with high affinity (dissociation constant, Kd, 1-12 nM) to a number of primary human tumors (n = 31) such as intestinal adenocarcinoma (n = 17; 150-4000 fmol/mg protein) or breast cancer (n = 4; 250-9000 fmol/mg protein).
"
5.
Adenocarcinoma
11/01/1999 - "
111In-/90Y-DOTALAN exhibited a similar high binding affinity (Kd, 1-15 nM) for the human breast cancer cell lines T47D and ZR75-1, the prostate cancer cell lines PC3 and DU145, the colonic adenocarcinoma cell line HT29, the pancreatic adenocarcinoma cell line PANC1, and the melanoma cell line 518A2.
"
11/01/1999 - "
111In-/90Y-DOTALAN bound with high affinity (dissociation constant, Kd, 1-12 nM) to a number of primary human tumors (n = 31) such as intestinal adenocarcinoma (n = 17; 150-4000 fmol/mg protein) or breast cancer (n = 4; 250-9000 fmol/mg protein).
"
Related Drugs and Biologics
1.
Proteins (Proteins, Gene)
Related Therapies and Procedures
1.
Therapeutics